November 18th, 2026NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.Read more
November 14th, 2026The OncFive: Top Oncology Articles for the Week of 11/8The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.Read more
November 13th, 2026FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBCThe FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.Read more
November 13th, 2026CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 InhibitionA European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.Read more
November 11th, 2026LITESPARK-022 PRO Data Further Support Adjuvant Belzutifan Plus Pembrolizumab in ccRCCThomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.Read more
November 7th, 2026VET3-TGI Generates Responses in Checkpoint Inhibitor–Refractory Cutaneous CancersVET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.Read more
November 6th, 2026Canakinumab Reduces Nodule Size in High-Risk Lung PrecancersIL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.Read more
November 6th, 2026VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILsVGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.Read more